TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01741831

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
Study: NCT04383743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo standard of care radical cystectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study: NCT04096781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDMT
Description: The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The participants will receive usual care.
Study: NCT02368158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
Description: During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
Description: During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
Study: NCT01157962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy in cervical cancer
Description: Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy in cervical cancer
Description: Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
Study: NCT04509024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incidental training
Description: Training involving non-speech sounds embedded in a video-game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit training
Description: Training involving explicit sound and category information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom training
Description: Structured adult classroom language training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom and incidental training
Description: Both classroom and incidental training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom and explicit training
Description: Both classroom and explicit training.
Study: NCT04034381

Intervention type: OTHER
Intervention: No intervention (descriptive survey only)
Description: No intervention
Study: NCT03612297

Intervention type: DIAGNOSTIC_TEST
Intervention: Selective reporting of Antibiotic Susceptibility Tests
Description: Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
Study: NCT02532790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1.5mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI
Description: 0.2-0.3mg/kg/d
Study: NCT03190161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music session
Description: Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
Study: NCT01858090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group Chirocaine
Description: Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group sufentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ephedrine
Description: If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine sulfate
Description: A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate
Description: A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate
Description: A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide (10 mg IV) was administered for nausea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide (10 mg IV) was administered for nausea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide (10 mg IV) was administered for nausea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: for severe pruritus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: for severe pruritus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: for severe pruritus
Study: NCT04598100

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS-EC
Study: NCT05466604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase Injection mesomedica
Description: injection of 150 IU hyaluronidase to perioperative region, submucosally.
Study: NCT01858090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pethidine hydrochloride
Description: pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine hydrochloride
Description: pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine hydrochloride
Description: pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac sodium
Description: as additional analgesic among cases in which VAS\>3(Postoperatively)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: as additional analgesic among cases in which VAS\>3(Postoperatively)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: as additional analgesic among cases in which VAS\>3(Postoperatively)
Study: NCT03326791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Trombyl 160 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo one tablet daily
Study: NCT03448822

Intervention type: PROCEDURE
Intervention: sentinel node procedure
Description: a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
Study: NCT03876431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy-Flex
Description: The Easy-Flex device will be used to increase knee flexion and extension ROM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
Study: NCT02670798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastography laboratory testing
Description: Laboratory test that monitors clotting properties of blood
Study: NCT02351687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Nutrient Supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednet
Study: NCT04612842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
Study: NCT04211987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast track care protocol
Description: fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care protocol
Description: standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
Study: NCT02088593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Dawn Light Box
Description: per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene instructions
Description: Sleep Hygiene instructions read aloud
Study: NCT05466604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone dekort
Description: injection of 8 mg dexamethasone to perioperative region, submucosally.
Study: NCT03136029

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant
Description: Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Description: Daily consumption of BH4 (10mg/kg)
Study: NCT02088593

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene instructions
Description: Sleep Hygiene instructions read aloud
Study: NCT01804582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Navigator consultation
Description: Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan.
Study: NCT01468610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine
Description: 50-100 mg daily for 8 weeks
Study: NCT04634708

Intervention type: OTHER
Intervention: No intervention
Description: No intervention due to observational design
Study: NCT02393846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Description: Topical ketoprofen as used in gel form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
Study: NCT03136029

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tetrahydrobiopterin (BH4)
Description: Daily consumption of BH4 (10mg/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise training
Description: Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
Study: NCT02017366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
Study: NCT01959594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-06412562
Description: oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
Study: NCT03919513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory pressure threshold device
Description: The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
Study: NCT00679146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside+Ketoprofen
Description: 1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside
Description: 2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
Study: NCT01523574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 400mg PO orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given orally
Study: NCT02257177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DPI placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DPI placebo
Study: NCT01980277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2780301 + paclitaxel
Description: Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
Study: NCT01123915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) Medium dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) High dose
Study: NCT01630551

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fishoil supplement
Description: 1 capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 1 capsule per day
Study: NCT02008513

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE® AD02

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE® AD02

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03679637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-based aphasia therapy
Description: patients will independently practice with a speech app during hospitalisation
Study: NCT02969590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen and Progesterone Replacement
Description: Replace hormones exogenously to create an artificial cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen and Progesterone Replacement
Description: Replace hormones exogenously to create an artificial cycle
Study: NCT03325075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAL-181388
Description: Escalating dose levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00869856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 solution for s.c. administration
Description: Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
Study: NCT04565717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HSD
Description: ALN-HSD will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HSD
Description: ALN-HSD will be administered by subcutaneous (SC) injection.
Study: NCT01123915

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dimethyl Sulfoxide
Study: NCT04565717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HSD
Description: ALN-HSD will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
Study: NCT03541369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 427
Description: AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 427
Description: AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.